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CHAPTER 1: INTRODUCTION
A cell is a basic structural and functional unit of all living organisms. The human body is
composed of millions of cells; all these cells require an energy source for their normal
functioning. Glucose, a monosaccharide is the primary source of energy for cells in the body.
Glucose metabolism plays an important role in the human body and is regulated by an interplay
between the pancreatic hormones glucagon and insulin to maintain glucose homeostasis [1, 2].
Glycogenolysis, gluconeogenesis and glycolysis also play a key role in glucose metabolism. It is
well established that chronic exposure of pancreatic β-cells to hyperglycemic conditions leads to
the onset of cell dysfunction and diabetes.
The pancreas, the key regulator of glucose metabolism, functions as an exocrine gland
[secreting digestive enzymes] as well as an endocrine gland [secreting hormones such as insulin
and glucagon]. The endocrine cells of the pancreas are grouped together to form the islets of
Langerhans [3]. The different endocrine cells include α-cells, β-cells, δ-cells, γ-cells and ε-cells.
The α-cells produce the hormone glucagon which increases the blood sugar levels and make
about 15-20% of the total islet count whereas the β-cells produce the blood glucose level
reducing hormone insulin and constitute about 65-80% of the total cells [3]. The δ-cells
constitute 3-10% of the islets and produce somatostatin which inhibits the secretion of both
glucagon and insulin [3]. The γ-cells (3-5%) produce pancreatic polypeptide (PP) [4] and ε-cells
(<1%) produce ghrelin [5].

2

Figure 1-1: Image of a pancreatic islet: insulin (green) and glucagon (red).
[diabetesresearch.org]
Glucotoxicity:
Prolonged exposure of the β-cells to high glucose [glucotoxic ] conditions results in
permanent damage to the β-cells, including defects in insulin gene transcription and expression
[6]. Glucotoxic conditions promote generation of reactive oxygen species [ROS] mediated by
Rac1-Nox2 signaling axis. This, in turn, leads to activation of stress kinases resulting in
mitochondrial dysfunction and increased Caspase activity leading to β-cell death [7]. High
glucose concentrations also cause an impaired Glucose Stimulated Insulin Secretion (GSIS).
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Figure 1-2: Glucotoxic conditions lead to β-cell death: Prolonged exposure to HG conditions
activate Rac1-Nox2 mediated ROS generation pathway leading to stress kinase activation
eventually culminating in β-cell death. [Image taken from Syed et al. ref (7)]
Glucose Stimulated Insulin Secretion (GSIS):
GSIS is initiated when glucose enters the pancreatic β-cell via GLUT2 transporters and
then undergoes cationic and metabolic events that lead to increased intracellular ATP
concentration causing the closure of KATP channel. The KATP channel closure causes membrane
depolarization followed by opening of the Voltage dependent calcium channels (VDCC) causing
an increased influx of Ca2+ ions into the β-cell and the Ca2+ influx mediates the mobilization of
insulin granules to the plasma membrane for insulin exocytosis [8, 9]. High glucose
concentrations/glucotoxic conditions induce impaired GSIS by partially inhibiting the K ATP
channel, thereby decreasing the K+ efflux and Ca2+ influx [6].
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Figure 1-3: Glucose Stimulated Insulin Secretion (GSIS): a simplified model. [Wang et al.
ref (8)].
Diabetes:
According to the International Diabetes Federation (IDF), diabetes is a chronic disease
characterized by body's inability to produce insulin or use insulin effectively, thereby leading to
increased glucose levels that impact the pancreatic β-cell negatively resulting in β-cell death
and/or insulin resistance. There are 3 types of diabetes- Type 1, Type 2 and gestational diabetes.
Diabetes can cause different complications leading to cardiovascular diseases, kidney failure,
diabetic retinopathy, nerve diseases, limb amputations and pregnancy complications.
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Type 1 Diabetes:
Type 1 diabetes, also referred to as insulin dependent diabetes mellitus (IDDM) is due to
autoimmune reactions in which the pancreatic β-cells are destroyed by the immune system and
insulin is no longer produced in the human body. Viral infections and family history of type 1
diabetes are the associated risk factors for type 1 diabetes. B lymphocytes have been viewed as
key players in development of type 1 diabetes by producing autoantibodies and by presenting
antigens to T lymphocytes [10]. Animal studies by Hu et al. and Guleria et al. have shown that
anti B cell therapy restores normal glucose levels and reverses diabetes [11, 12]. However, "In
human disease, the function of B lymphocytes is less obvious and the desire to directly link
murine pathogenesis of type 1 diabetes to that of humans (despite the profound differences in the
immune systems between the two species) has led to various misconceptions and false
expectations" [13-16].
Type 2 Diabetes:
In type 2 diabetes, formerly known as non-insulin dependent diabetes mellitus (NIDDM),
the pancreatic β-cells become resistant to insulin and are unable to utilize the insulin effectively
in lowering blood glucose levels, thus, leading to hyperglycemia. T2DM alters the glucose
homeostasis by inducing impaired nutrient storage and mobilization and triggers the pancreatic
β-cells to enhance insulin secretion in response to insulin resistance [17]. Obesity, unhealthy
diet, high blood pressure are some of the known factors that can lead to type 2 diabetes. Other
studies have shown that very low energy diet (VLED)/ very low calorie diet (VLCD) can prove
beneficial to patients with type 2 diabetes [18-20].
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Gestational Diabetes:
When the slightly elevated blood glucose levels in females during pregnancy cause an
imbalance between elevated insulin secretion and pregnancy induced insulin resistance resulting
in the onset of gestational diabetes [21]. Furthermore, in addition to insulin resistance,
gestational diabetes is known to alter glucose metabolism and tolerance [22].
The number of people being diagnosed with diabetes is on the increase and according to
an estimate by IDF, there will be 642 million individuals with diabetes in 2040 as opposed to 415
million in 2015. The number of deaths due to diabetes in 2015 were 5 million, which was higher
than the deaths due to HIV/AIDS, tuberculosis and malaria combined [23].

Figure 1-4: Prevalence of Diabetes around the world [International Diabetes Federation Atlas
2015]
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Metformin:
Metformin is an oral antidiabetic drug which is used as a first-line therapy for patients
diagnosed with T2DM [24-26]. Metformin lowers elevated blood glucose levels by suppressing
hepatic glucose production, increasing peripheral glucose uptake and ameliorating insulin
sensitivity [25, 27-29]. It has been shown to improve vascular endothelial functions and reduce
cardiovascular events in patients with type 2 diabetes [30]. The oral bioavailability of Metformin
is 50-60% with majority of the absorption being completed within ~ 6 hours in the small
intestine and the drug gets minimally metabolized in the liver before being excreted by the
kidneys [31].

Figure 1-5: Structure of Metformin [https://pubchem.ncbi.nlm.nih.gov]
Hypothesis:
Glucotoxicity, as discussed earlier, induces the Rac1-Nox2 mediated stress kinase
activation, thereby producing mitochondrial defects and eventually leading to β-cell death [7].
Based on these observations, we asked if metformin, an oral antidiabetic drug for T2DM can
potentially provide protection to the pancreatic β-cells from HG-induced mitochondrial
dysfunction. Specifically, we hypothesized that metformin triggers its cyto-protective roles by
inhibiting the HG-induced Rac1 mediated stress kinase activation signaling pathway. We
validated this hypothesis in insulin-secreting INS-1 832/13 cells incubated cultured under
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glucotoxic conditions in the absence or presence of clinically-relevant concentrations of
metformin. Our findings indicate that metformin affords significant protection in pancreatic βcell against HG-induced metabolic events leading to its dysfunction.
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CHAPTER 2: MATERIALS AND METHODS
Chemicals and antibodies:
Rabbit polyclonal antibody for phospho-p38MAPK (Thr 180/Tyr 182), total-p38MAPK,
Lamin B and mouse monoclonal antibody for CD36 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Antisera directed against phospho-p53, total-p53, phosphoJNK1/2, total-JNK1/2 and cleaved caspase-3 antibodies were purchased from Cell Signaling
(Danvers, MA). Antibodies against Bcl2 and actin were from Sigma–Aldrich (St. Louis, MO).
Phospho-VAV2 and total-VAV2 antisera were purchased from Abcam (Cambridge, MA). NEPER Nuclear and Cytoplasmic Extraction Kit was from Thermo Scientific (Waltham, MA).
IRDye® 800CW anti-rabbit and anti-mouse secondary antibodies were obtained from LICOR
(Lincoln, NE). Metformin hydrochloride, MTT, DMSO were purchased from Sigma-Aldrich (St.
Louis, MO). Rac1 Antibody was from BD Transduction lab (San Jose, CA). Rac1 activation
assay Biochem kit was purchased from Cytoskeleton, Inc (Denver, CO). EHT 1864 [Rac1
inhibitor], was purchased from R&D systems (Minneapolis, MN). All other reagents used in the
studies were obtained from Sigma–Aldrich (St. Louis, MO).
Insulin-secreting INS-1 832/13 cells and culture conditions:
INS-1 832/13 cells were provided by Dr. Chris Newgard, Duke University Medical
Center (Durham, NC). INS-1 832/13 cells were cultured in RPMI 1640 medium containing 10%
heat-inactivated FBS supplemented with antibacterial antifungal (100IU penicillin and 100IU/ml
streptomycin), 1mM sodium pyruvate, 50 µM 2-mercaptoethanol and 10mM HEPES (pH 7.4) at
37°C and 5% CO2 in a humidified incubator. INS-1 832/13 cells were sub cloned twice weekly
following trypsinization and passages 53-61 were used for the studies. Following overnight
incubation in 2.5 mM glucose and 2.5% serum RPMI media, the cells were treated with low
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glucose (2.5 mM; LG) or high glucose (20mM; HG) in the absence or presence of MF (15 µM
and 30 µM) and EHT 1864 (10 µM) for 24 hours.
Western Blotting:
After 24-hour incubation with glucose (2.5mM, LG and 20mM, HG) in the absence and
presence of metformin (15 µM and 30 µM) and EHT 1864 (10 µM), cells were lysed using RIPA
buffer containing protease inhibitor cocktail, 1mM NaF, 1mM PMSF and 1mM Na3VO4. Cell
lysates (~45 µg for INS-1 832/13 cells) were then resolved by SDS-PAGE, and then transferred
onto nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk in PBS-T
buffer or 0.1% Casein in PBS-T and then incubated with appropriate primary antibody diluted
with 5% non-fat dry milk in PBS-T buffer or 0.1% Casein in PBS-T, overnight at 4°C. The
membranes were then washed 5 x 5 minutes with PBS-T, and then probed with the appropriate
secondary antibody IRDye

®

then detected using Odyssey

800CW anti-rabbit or anti-mouse. The immune complexes were
®

Imaging Systems. The band intensities were quantifies using

Carestream ® Molecular Imaging Software.
Rac1 activation assay:
Rac1 activation assay was performed using Rac1 pull-down activation assay kit (bead
pull-down format; Cytoskeleton Inc.) using manufacturers’ protocol. Briefly, INS-1 832/13 cells
were grown to ~70% confluence in complete growth media (RPMI). Cells were then grown in
low glucose (2.5mM) low serum (2.5%) starvation media overnight followed by culture in LG
and HG media in the presence and absence of metformin (0-30 µM). After 24 hours, growth
media was aspirated and cells were washed with ice cold PBS. After complete removal of PBS,
ice cold lysis buffer containing 1X protease inhibitor cocktail were added to culture covering
entire surface. Cell lysates were collected and snap frozen in liquid nitrogen and stored at -70 0 C
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until further processing. Pull-down assay was performed the same day using the snap frozen
protein lysates.
Isolation of nuclear and non-nuclear fractions:
INS-1 832/13 cells were treated with low glucose or LG (2.5mM) and high glucose or
HG (20mM) in the presence and absence of metformin (30µM) for 24hrs as described above.
Adherent cells were harvested with trypsin-EDTA and the cell pellet was washed once with ice
cold 1X PBS. The cytoplasmic and nuclear protein fractions were collected using NE-PER
nuclear and cytoplasmic extraction Kit (Thermo Scientific) following manufacturer’s protocol.
Cytoplasmic protein extract and nuclear protein extract were further analyzed by western
blotting. The purity of the nuclear fractions was assessed by probing for nuclear Lamin B.
Cell Viability Assay:
MTT assay was performed using INS-1 832/13 cells to quantify cell viability under LG
(2.5mM) and HG (20mM) conditions in the presence and absence of MF (30 µM). INS-1 832/13
cells were starved in low glucose (2.5mM) low serum (2.5%) starvation medium for 12-18 hrs in
a 96 well plate. Following starvation, the INS-1 832/13 cells were treated with LG or HG in the
absence or presence of MF (30 µM) for 24 hrs. After the 24-hour incubation, the cells were
incubated with MTT for a period of 2-4 hrs. At the end of the incubation, DMSO was added to
the wells to solubilize the MTT crystals. The absorbance was measured at 540nm using GEN 5.0
software.
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CHAPTER 3: GLUCOTOXICITY INDUCES Rac1 ACTIVATION AND NUCLEAR
TRANSLOCATION AND CD36 EXPRESSION IN INS-1 832/13 CELLS
The studies conducted in this Chapter are based on the recent findings from our
laboratory suggesting that glucotoxic conditions induce impaired GSIS, β-cell dysfunction and
apoptosis by triggering a Rac1-Nox2 mediated stress kinase activation signaling pathway [7, 9].
Three classes of G-proteins that have been identified in the pancreatic β-cells are: 1) The
heterotrimeric proteins involved in signal transduction via G-protein coupled receptors (GPCRs)
to the intracellular effectors [32, 33]. 2) small G-proteins, which are involved in membrane
trafficking of secretory vesicles and cytoskeletal remodeling [34]. 3) The third class of Gproteins includes the elongation factors and Tau proteins [33, 34].
HG conditions promote nuclear accumulation of Rac-1 in INS-1 832/13 cells, normal rat
islets and human islets
Previous observations from our laboratory have demonstrated sustained activation of Rac1 in
INS-1 832/13 cells, normal rat islets and human islets exposed to HG conditions [7, 35, 36]. We
provided evidence to indicate a significant reduction in geranylgeranyltransferase [GGTase]
activity, which regulates post-translational prenylation of small G-proteins, including Rac1. As
an index for decreased prenylation, we observed significant accumulation of unprenylated
proteins in pancreatic β-cells exposed to HG conditions. Therein, we speculated that
unprenylated, but paradoxically active G-proteins might translocate into “inappropriate”
compartments [e.g., nucleus] to induce metabolic defects in the effete β-cell [37]. Therefore, we
undertook the current investigation to determine potential targeting of Rac1 into the nuclear
compartment in pancreatic β-cells exposed to HG conditions. Data depicted in Figure 1 [Panels
A and B] demonstrate a marked increase in the nuclear localization of Rac1 in INS-1 832/13
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cells exposed to glucotoxic conditions. These findings were confirmed in normal rodent islets
[Figure 1; Panels C and D] and human islets [Figure 1; Panel E]. Together, these observations
validate our hypothesis that exposure of insulin-secreting cells to HG conditions leads to
sustained activation of unprenylated Rac1 leading to its translocation to the nuclear
compartment.

INS-1 832/13 cells
LG

B

4
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Figure 3-1: HG conditions promote nuclear accumulation of Rac-1 in INS-1 832/13 cells,
normal rat islets and human islets: Panel A: Relative abundance of Rac1 in the nuclear
fractions isolated from INS-1 832/13 cells exposed to LG or HG conditions was determined by
Western blotting. Panel B: Pooled data from three independent experiments is shown.
Accumulation of Rac1 was calculated as a ratio of Rac1 to Lamin B in the nuclear fraction
[loading control as well as marker] and represented as fold change over basal. ** p<0.005 vs
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2.5mM glucose. Panel C: Relative abundance of Rac1 in the nuclear fractions isolated from
normal rat islets exposed to LG or HG conditions was determined by Western blotting. Panel D:
Pooled data from three independent experiments is represented herein. Accumulation of Rac1
was calculated as above. ** p<0.005 vs 2.5mM glucose. Panel E: Human pancreatic islets were
incubated with LG or HG for 24 hours and relative abundance of Rac1 in the nuclear fraction
was determined by Western blotting. Western blot of one batch of human islet lysates is provided
here.
Metformin attenuates HG-Induced Rac1 activation and Rac1 nuclear translocation
Small G-proteins play an important role in regulating glucose stimulated insulin secretion
(GSIS). There are 3 major classes of small g-proteins. The first group includes Cdc42, Rac1, Rho
and ADP-ribosylation factor-6 (ARF-6). The second group consists of Rap1, Rab3A and Rab27.
The third group of small G-proteins consist of Rab2, Rhes and Rem2 [34].
Our experimental model was focused on investigating whether clinically relevant
concentrations of metformin, a biguanide antidiabetic compound, protects INS-1 832/13 cells
from HG-induced sustained activation and translocation of Rac1, thereby halting the apoptotic
signaling events leading to β-cell death. To address this, INS-1 832/13 cells were exposed to HG
conditions in the presence and absence of metformin [30μM] and Rac1 activation was assessed
using pull down assay. Data shown in figure 3-2 indicate significant increase in Rac1 activation
and nuclear translocation in INS-1 832/13 cells exposed to HG conditions and co-provision of
metformin significantly abated the HG-induced Rac1 activation and nuclear translocation. An
interesting observation was that in addition to reducing HG-induced Rac1 activation, metformin
induced slight Rac1 activation in cells exposed to basal [normal] glucose conditions [Figure 3-2,
Panel A]. Pooled data from multiple experiments is depicted in Figure 3-2 [Panel B]. Metformin
treatment also reduced HG-induced Rac1 nuclear translocation in INS-1 832/13 cells [Figure3-2,
Panel C]. Quantified data from multiple experiments is represented in Figure 3-2 [Panel D].
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Together, findings from these experiments demonstrate metformin's beneficial effect in
inhibiting the HG-induced Rac1 activation and nuclear translocation in INS-1 832/13 cells.
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Figure 3-2: Metformin suppresses HG-induced Rac1 activation and Rac1 nuclear
translocation in INS-1 832/13 cells: Panel A: INS-1 832/13 cells were cultured in LG (2.5mM)
or HG (20mM) for 24 hours in the absence and presence of Metformin (30 µM). Rac1 activation
assay was performed using pull-down activation assay biochem kit [see Methods for additional
details]. Cell lysates were separated and analyzed using western blotting. Panel B: Band
intensities of Rac1 were quantified by densitometric analysis. Abundance of active Rac1 in pulldown samples was normalized by total Rac1. Pooled data from three experiments was
represented in this panel. *p < 0.05 vs. 2.5mM glucose alone, **p < 0.05 vs. 20mM glucose
alone. Panel C: INS-1 832/13 cells (a) were incubated with LG (2.5mM) and HG (20mM) in the
absence and presence of metformin (0-30 µM) for 24 h. Cell lysates were analyzed for Rac1
using western blotting. Purity of the nuclear fractions was verified by probing with Lamin B.
Panel D: Band intensities for Rac1 were measured using densitometry and the ratios were
calculated over Lamin B in the presence and absence of metformin (n=3 in INS-1 832/13 cells).
*p < 0.05 vs. 2.5 mM glucose alone, **p < 0.05 vs. 20mM glucose alone.
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Guanine nucleotide exchange factors (GEFs)
There are various regulatory proteins/factors that enable the G-proteins to switch between
the active (GTP-bound) and inactive (GDP-bound) conformations, and these factors are
classified into 3 major categories. The first group consists of the guanine nucleotide exchange
factors (GEFs), which facilitate GDP-GTP exchange [switch from inactive to active states]. The
second group includes the GDP- dissociation inhibitors (GDIs) that retain putative G-proteins in
their GDP-bound [inactive] conformation by complexing with GDP-bound G-proteins. The third
group consists of GTPase-activating proteins (GAPs) which mediate inactivation of G-proteins
by hydrolyzing the GTP-bound to G-proteins to their inactive GDP-bound forms [33]. As
depicted in Figure 3-2, T-lymphocyte invasive and metastasis protein 1 (Tiam1) and Vav2
represent the two GEFs for Rac1 [33]. Our experimental design was focused on investigating
whether co-provision of a clinically relevant concentration of metformin would inhibit Vav2 and
thus, prevent conversion of inactive Rac1 to its active confirmation.
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Figure 3-3: Guanine nucleotide exchange factors: [A schematic depicting the conversion of
inactive Rac1 to its active GTP-bound confirmation by guanine nucleotide exchange factors
(Tiam1 and Vav2) and conversion of active to inactive confirmation by GTPase-activation
proteins. ref. (33)]
Guanine nucleotide exchange factor Vav2 (Vav2) and regulatory effects of metformin
Guanine nucleotide exchange factor Vav2 (Vav2) is one of the regulator proteins that
induces the GDP/GTP exchange for Rac1 and belongs to the diffuse B-cell lymphoma (Dbl)
family of proteins and is ubiquitously distributed [38, 39]. Vav2 is activated by tyrosine
phosphorylation

on

phosphatidylinositol

epidermal

growth

factor

receptor

(3,4,5)-triphosphate

(PIP3)

generated

(EGFR)
by

and

interacts

with

phosphatidylinositol-4,5-

biphosphate 3-kinase (PI3K) [40-42].
According to the data published by Veluthakal et al.[39], Vav2 phosphorylation increases
under glucotoxic conditions and it is the increased Vav2 phosphorylation that mediates the Rac1
activation and glucose stimulated insulin secretion. Based on these findings, we asked if
metformin treatment of the INS-1 832/13 cells could result in Vav2 inhibition and thereby,
inhibit the conversion of inactive Rac1 to active Rac1. The data accrued from the studies,
showed that Vav2 phosphorylation increased in INS-1 832/13 cells exposed to HG-conditions. It
is noteworthy, however, that metformin treatment did not restore the Vav2 phosphorylation to
normal levels, but instead induced an increased Vav2 phosphorylation in cells exposed to LG
conditions. Together, these findings suggest that metformin does not inhibit Vav2
phosphorylation even though it inhibited HG-induced Rac1 activation in INS-1 832/13 cells.
These data indicate alternate mechanisms might exist for metformin-induced effects.
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Figure 3-4: Metformin fails to inhibit HG-induced Vav2 phosphorylation in INS-1 832/13
cells: Panel A: INS-1 832/13 cells were treated with LG (2.5mM) and HG (20mM) in the
absence or presence of Metformin (30 µM) for 24 h. Cell lysates were separated and analyzed
using western blotting for phosphorylated and total Vav2. Panel B: Band intensities for
phospho-Vav2 were measured using densitometry and the ratios were calculated over total-Vav2
in the presence of metformin (n=3 in INS-1 832/13 cells). *p < 0.05 vs. 2.5mM glucose alone.
Gluco or glucolipotoxic conditions induce CD36 expression
Cho et al. have demonstrated that CD36, a class B scavenger receptor, plays critical
regulatory roles in numerous physiological and pathological functions by inducing distinct
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cellular responses in multiple cell types such as cardiac muscle, skeletal muscle and adipocytes
[43]. Cluster of Differentiation 36 or Cluster Determinant 36(CD36) is a fatty acid transporter,
membrane protein that mediates glucotoxicity induced β-cell dysfunction by increasing the
transport of fatty acids into the pancreatic beta cell and undergoes HG-induced increased
expression in the intestinal epithelial cells [26, 44-46]. According to the data published by Wallin
and associates, overexpression of CD36 inhibits the glucose mediated fatty acid oxidation and
also resulted in impaired glucose stimulated insulin secretion mediated by fatty acids [47].
Several recent studies have established novel roles for CD36 in the onset of HG-induced
β-cell dysfunction and death. Based on these observations, we asked if HG-conditions increase
expression of CD36 in INS-1 832/13 cells, and if so, if Rac1 activation represents an upstream
signaling mechanism for HG-induced CD36 expression. We further questioned if metformin
exerts any protective effects on HG-induced CD36 expression.
HG-induced CD36 expression in INS-1 832/13 cells: Protection by metformin
In the next of studies we asked if metformin prevents HG-induced CD36 expression in
INS-1 832/13 cells. Data in Figure 3-5 demonstrate a significant increase in the expression of
CD36 in INS-1 832/13 cells following exposure to HG conditions. In addition, co-provision of
metformin markedly suppressed HG-induced expression of CD36. It is noteworthy, however,
like Rac1 activation [Figure 3-1], metformin treatment slightly increased CD36 expression under
basal glucose conditions [Figure 3-5; Panel A; lane 1 vs. 2]. Pooled data from multiple
experiments are included in Figure 3-5 [Panel B]. Compatible with data described above [Figure
3-2], findings from this experiment suggest that HG-induced rac1 activation and nuclear
translocation and downstream CD36 expression are sensitive to metformin.
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Figure 3-5: Metformin inhibits HG-induced CD36 expression: Panel A: INS-1 832/13 cells
were treated with LG (2.5mM) and HG (20mM) with and without Metformin [30μM] for 24 hrs.
Cell lysates for CD36 were separated using western blotting and actins were used as loading
control. Data are representative of three experiments. Panel B: Quantification of the CD36 and
actin bands was done using densitometric analysis and ratios were calculated over actins in the
presence and absence of metformin. (n=3 in INS-1 832/13 cells). *p < 0.05 vs. 2.5mM glucose
alone.
Reversal of glucotoxicity and lipotoxicity induced CD36 expression by EHT 1864
It has been established that glucotoxic and glucolipotoxic conditions mediate β-cell
dysfunction by inducing CD36 overexpression [26, 44-47]. EHT 1864 is a small molecule Rac1
inhibitor that prevents Rac1 activation by inhibiting the switch from inactive to active
confirmation, thereby, keeping the G-protein in the inactive state [48]. To address the question of
whether Rac1 activation represents an upstream signaling mechanism for HG-induced CD36
expression, we quantified HG-induced expression of CD36 in INS-1 832/13 cells exposed to
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EHT 1864. Data in Figure 3-4 indicate a significant increase in the CD36 expression in INS-1
832/13 cells exposed to glucotoxic and lipotoxic conditions. Moreover, HG-induced expression
of CD36 was markedly reduced following inhibition of Rac1, thus suggesting that Rac1
activation may be upstream to CD36 expression in β-cells exposed to HG and lipotoxic
conditions.
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Figure 3-6: Glucolipotoxic conditions induce CD36 expression: regulation by Rac1: Panel
A: INS-1 832/13 cells were treated with low glucose (2.5mM), high glucose (20mM) and
palmitate (0.5mM) for 24 hrs in the presence and absence of EHT 1864 (10 μM ). Cell lysates for
CD36 were separated using western blotting and actins were used as loading control. Data are
representative of three experiments. *p < 0.05 vs. 2.5 mM glucose alone, **p < 0.05 vs. 20mM
glucose alone.
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Summary of findings:
 High glucose conditions induce increased Rac1 nuclear accumulation in INS-1 832/13
cells, primary rodent islets and human islets
 Glucotoxicity-induced Rac1 activation and nuclear translocation was attenuated by
metformin
 HG-induced Vav2 phosphorylation was unaffected by metformin treatment
 Increased CD36 expression in response to HG conditions was reduced by metformin
 EHT 1864 inhibited CD36 expression
 CD36 may be downstream of Rac1
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CHAPTER

4:

GLUCOTOXIC

CONDITIONS

PROMOTE

STRESS

KINASE

ACTIVATION AND PANCREATIC ISLET β-CELL DYSFUNCTION AND DEMISE
Based on the findings of Syed et al. and Sidarala et al., we now have an understanding
that glucotoxic conditions lead to β-cell dysfunction and apoptosis induced via stress kinase
(p38MAPK and JNK1/2) and p53 activation [7, 9, 49]. Inflammation and several other stress
stimuli lead to the activation stress kinases (mainly serine/threonine kinases) and hence cause
impaired insulin signaling [50]. There are 3 types of Mitogen-activated protein kinases (MAPK)
and these includes extracellular signal-regulated kinases (ERK), p38MAPK and the cJun Nterminal kinases (JNK). Differentiation signals and mitogens activate the ERKs whereas
p38MAPK and JNK are activated by stress stimuli and are referred to as stress-activated kinases
(SAPK) and these MAPK lead to the increased expression of certain inflammatory cytokines [51,
52]. The tumor suppressor p53 plays a critical role in mediating apoptosis and tumor suppression
via transcriptional regulation of downstream targets after the cells have been exposed to
genotoxic stress [53, 54]. Under normal conditions, the proteasome degradation pathway keeps a
control on the levels of p53 [54]. There are several enzymes such as kinases, phosphatases,
acetyltransferases, deacetylases, ubiquitin ligases, deubiquitinases, methylases, and sumoylases
that play a crucial role in stabilizing p53 [54-56]. Based on the findings mentioned above, we
asked if HG-induced stress kinase (p38MAPK and JNK 1/2) and p53 activation could be
inhibited by co-provision with clinically relevant concentrations of metformin in INS-1 832/13
cells.
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p38MAPK and JNK 1/2 activation mediated by glucotoxic conditions is prevented by
metformin
There are 4 different isoforms of p38MAPK and these include alpha, beta, gamma and
delta [52]. Different tissues express these isoforms differently. The brain tissue expresses less
p38α isoform whereas the δ isoform is abundant in tissues such as endocrine glands and
neutrophils, p38γ is found in almost all the tissues with abundance in muscle tissue and p38β
isoform is the main isoform [51, 57-61]. "All p38 isoforms are activated, in response to
appropriate stimuli, by dual phosphorylation in the activation loop sequence Thr-Gly-Tyr" [51].
It has been well established that glucotoxic conditions induce an increased p38MAPK
activation which mediates pancreatic β-cell dysfunction and demise by mediating p53 expression
and metabolic dysfunction [49]. Based on the findings of Sidarala et al., we designed an
experiment to assess whether co provision with metformin (15 & 30 µM) attenuated p38MAPK
phosphorylation in INS-1 832/13 cells exposed to HG conditions. Quantification of HG-induced
activation of p38MAPK demonstrated a significant stimulation in INS-1 832/13 cells [Figure 41]. Metformin treatment significantly alleviated such effects. Interestingly, however, as in the
case of Rac1 activation [Figure 3-1], Vav2 phosphorylation [Figure 3-3] and CD36 expression
[Figure 3-5], metformin treatment increased p38MAPK activation under basal glucose
conditions despite its protective effects against high glucose-induced Rac1 activation, CD36
expression and p38MAPK activation.
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Figure 4-1: Metformin inhibits HG-induced p38MAPK activation: Panel A: INS-1 832/13
cells were incubated with LG [2.5mM] and HG [20mM] in the presence and absence of
metformin [0-30 µM] for 24 h. Western blotting was used to separate and analyze the cell lysates
for phopho-p38MAPK and total-p38MAPK. Panel B: Quantification of the phopho-p38 bands
was done by densitometry and the ratios were calculated over total-p38 in the presence of
metformin [n=5]. *p < 0.05 vs. 2.5mM glucose alone, **p < 0.05 vs. 20mM glucose alone; NS:
not significant.
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HG-induces JNK1/2 activation: Regulation by metformin
cJun N-terminal kinase (JNK) is activated by stress stimuli and is also referred to as
stress -activated kinase (SAPK). JNK1, JNK2 and JNK 3 are the three genes that encode for JNK
[51]. JNK1 and JNK 2 are expressed ubiquitously whereas JNK 3 is expressed in brain, heart and
testis [62, 63]. Apoptosis, cell proliferation and cell migration play an important role in
mediating JNK to induce a specific response to a specific stimulus [51]. In case of dietary and
genetically mediated obesity, tissues such as adipose tissue, muscle tissue and liver have highly
activated JNK pathway [64-67]. In pancreatic β-cells, JNK pathway activation leads to the
inhibition of fatty acid induced GSIS via phosphorylation and inhibition of IRS1 and IRS2 [68].
According to the data published by Syed et al. and Kaneto et al. increased oxidative stress
induces JNK activation, thereby leading to pancreatic β-cell death [7, 69, 70].
Based on these findings, we questioned whether HG induces JNK 1/2 activation in INS-1
832/13 cells and if so, does metformin provide any protection to the cells by inhibiting the JNK
1/2 activation?. To address this question, we assessed the HG-induced JNK 1/2 activation in
INS-1 832/13 cells and the data depicted in Figure 4-2 depicted a significant increase in HGinduced JNK 1/2 activation. It is noteworthy, however, that co-provision with clinically relevant
concentrations of metformin only resulted in attenuating JNK 1 but not JNK 2 phosphorylation.
This specific inhibition of JNK 1 by metformin could be attributed to the fact that it is JNK 1
which is the key player in the development of obesity and insulin resistance [71] and the
substrate specificity due to splicing of one of the two alternate exons encoding for the kinase
domain might influence the JNK interaction with the docking sites on the substrate [72].
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Figure 4-2: HG-induced JNK 1/2 phosphorylation: reversal by metformin: Panel A: INS-1
832/13 cells were treated with LG (2.5mM) and HG (20mM) in the absence and presence of
metformin (30µM). Cell lysates for p-JNK 1/2 and total JNK 1/2 were analyzed and separated
using western blotting. Panel B: Densitometric analysis of the bands for p-JNK 1 was done and
the ratios were calculated over total JNK 1 in the presence and absence of metformin. Panel C:
Bands for p-JNK 2 were analyzed by densitometry and the ratios were calculated over total-JNK
2 in the presence and absence of metformin. [n=3]. *p < 0.05 vs. 2.5mM glucose alone, **p <
0.05 vs. 20mM glucose alone.
Metformin inhibits HG-mediated activation of p53 activation
In response to cell stress, p53 plays a pivotal role in activating/deactivating genes
involved in cell cycle arrest, DNA repair, senescence or apoptosis via post-translational events
such

as

ubiquitylation,

phosphorylation,

acetylation,

sumoylation,

methylation,

and

neddylation.[73-76]. "p53 functions primarily as a transcription factor and is biologically active
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as a homotetramer comprising 4 × 393 amino acid residues" [77]. As mentioned earlier, there are
several enzymes such as kinases, phosphatases, acetyltransferases, deacetylases, ubiquitin
ligases, deubiquitinases, methylases, and sumoylases that play a crucial role in stabilizing p53
[54-56]. In pancreatic β-cells, streptozotocin and palmitic acid increase the p53 activity and this
increased p53 activity leads to reduced β-cell proliferation, thereby, inducing glucose intolerance
and hypoinsulinaemia [78]. Data published by Sidarala et al. has shown HG induces p53
activation in INS-1 832/13 cells, rat islets, ZDF islets and human islets and treatment with
several pharmacological inhibitors (EHT 1864, Simvastatin, GGTI-2147, SB203580) inhibited
HG-induced p53 activation. Based on these findings, we questioned could metformin treatment
impart protection to INS-1 832/13 cells from HG-induced p53 activation. Data from Figure 4-3
represents a significant stimulation of p53 activation induced by glucotoxic conditions and coprovision with clinically relevant concentrations (15 and 30 µM) attenuated HG-induced p53
activation in INS-1 832/13 cells. It is noteworthy that, unlike in the case of Rac1 activation,
CD36 expression, p38MAPK and JNK1/2 activation, metformin did not exert any effects on p53
activation under basal glucose conditions.
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Figure 4-3: Metformin attenuates HG-induced p53 activation: Panel A: INS-1 832/13 cells
were treated with LG [2.5mM] and HG [20mM] in the absence or presence of metformin [0-30
µM] for 24 h. Cell lysates were separated and analyzed using western blotting for
phosphorylated and total p53. Panel B: Band intensities for phospho-p53 were measured using
densitometry and the ratios were calculated over total-p53 in the presence of metformin. *p <
0.05 vs. 2.5mM glucose alone, **p < 0.05 vs. 20mM glucose alone [n=3].
Summary of findings:
 HG-induced p38MAPK activation was reduced by metformin treatment
 Metformin inhibited HG-mediated phosphorylation of JNK 1 only
 p53 activation by glucotoxic conditions was prevented by metformin
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INDUCE

MITOCHONDRIAL

DYSFUNCTION LEADING TO CASPASE ACTIVATION AND APOPTOSIS
β-cell failure because of chronic exposure to PA or palmitic acid and high glucose is
induced by mitochondrial damage mediated by increased mitochondrial superoxide production
resulting in increased expression of uncoupling proteins [79, 80]. According to Fu et al.
increased mitochondrial uncoupling and subsequent decreased glucose stimulated ROS
production might lead to glucose or lipid induced β-cell death [80]. In case of diabetes there is a
change in the mitochondrial morphology as reported by Kabra et al. and Anello et al. [81, 82].
According M. Anello et al. islets from diabetic patients show a decrease in glucose-induced
mitochondrial membrane hyper polarization and decreased ATP levels, thereby resulting in an
uneven ATP'ADP ratio [81]. Mitochondrial dysfunction/damage results in release of cytochrome
c, Bax (pro-apoptotic) and Bcl2 (pro survival).
Based on the findings, the next set of studies were focused on investigating whether
exposure of INS-1 832/13 cells to glucose induce any changes in the levels of Bax and Bcl2 and
how do these changes affect the Caspase activation. We further asked if the deleterious effects of
HG-induced Bax, Bcl2 and Caspase activation could be reversed by co provision with
metformin.
HG-mediated Bax and Bcl2 expression: regulation by metformin
Bax is a pro apoptotic factor whereas Bcl2 is a pro-survival factor. For a cell to avoid
apoptosis, it is essential that the balance between Bax and Bcl2 activation remains unchanged
[83]. Bax and Bcl2 are involved in the intrinsic or the mitochondrial pathway of apoptosis
inducing alterations in the mitochondria leading to cytochrome c release and activation of
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caspases [84]. According to Schellenberg et al. Bax translocation from outer mitochondrial
membrane to cytosol via retrotranslocation and in response to apoptosis, retrotranslocation is
attenuated causing the mitochondrial Bax accumulation [85]. Bcl2 plays an important role in
regulating the decrease in mitochondrial membrane potential and inhibits the pro-apoptotic
proteins, thereby maintaining a balance to avoid apoptosis [85].
According to the data reported by Thurmond et al. INS-1 832/13 cells exposed to
glucolipotoxic conditions showed a decrease in HG-induced Bcl2 phosphorylation, suggesting
that glucolipotoxic conditions induce apoptosis [86]. In the next set of studies, we asked if HG
induced Bax activation and a Bcl2 deactivation. We also assessed whether metformin inhibited
Bax activation or restored Bcl2 activation in INS-1 832/13 cells. Data depicted in Figure 5-1
[Panels A-C] shows an increase in HG-induced activation of 2 isoforms of Bax (Bax α and Bax
β). It is noteworthy, however, that metformin treatment induced slight inhibition of only Bax α
isoform and had no effect on Bax β isoform. Further data from Figure 5-1 [Panel D] shows a
decrease in the activation of Bcl2 and co-provision with metformin was ineffective in restoring
the Bcl2 levels in INS-1 832/13 cells.
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Figure 5-1: Metformin suppresses HG-induced Bax phosphorylation and ineffective in
restoring Bcl2 levels: Panel A: INS-1 832/13 cells were treated with LG (2.5mM) and HG
(20mM) in the absence and presence of metformin (0-30 µM) for 24 h. Cell lysates were
analyzed for Bax using western blotting. Equal loading of proteins was confirmed using actin as
a loading control. Band intensities of Baxα were quantified using densitometry and the ratios
were calculated over actin in the presence of metformin. Panel B: Densitometric analysis was
used to quantify the Baxβ isoform intensities and ratios were calculated over actin with and
without metformin. *p < 0.05 vs. 2.5mM glucose alone, **p < 0.05 vs. 20mM glucose alone.
Panel C: INS-1 832/13 cells were treated with LG (2.5mM) and HG (20mM) in the absence and
presence of metformin (0-30 µM) for 24 h. Cell lysates were analyzed for Bcl2 using western
blotting. Actin was used as a loading control. Panel D: Band intensities of Bcl2 were quantified
using densitometry and the ratios were calculated over actin in the presence and absence of
metformin (n=3 in INS-1 832/13 cells). *p < 0.05 vs. 2.5mM glucose alone, **p < 0.05 vs.
20mM glucose alone.
Metformin reverses HG-induced activation of Caspase-3
“Caspases are evolutionarily conserved cysteine-aspartyl specific proteases that play a
key role in apoptosis” [87]. There are 14 caspases reported in mammals and some of them play a
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key role in apoptosis while the other caspases participate in cytokine activation [88, 89]. The “c”
in caspase represents the cysteine protease and the “aspase” refers to the caspase’s activity to
cleave after the aspartic acid residue [90]. Caspases are inactive initially and it is only the
cleavage of a specific aspartate cleavage site which makes a caspase functional in executing
apoptosis [90]. According to Fraser and Evan, some caspases activate the other caspases in a
subsequent manner, for instance, caspase 8 or initiator protease activates caspase 1 or the
amplifier protease which in turn induces the activation of machinery proteases or caspase
3/caspase 7 [91]. According to the experiments performed by Liadis et al. caspase 3 plays an
important role in β-cell apoptosis [87].
In the last series of experiments, we determined the degree of caspase-3 activation, a
marker for mitochondrial dysregulation, in INS-1 832/13 cells exposed to HG conditions in the
absence or presence of metformin. Our findings demonstrated a high degree of caspase-3
activation in cells exposed to HG conditions. This is evidenced by emergence of the cleaved
[biologically- active] caspase-3 band under these conditions [Figure 5-2; Panel A]. We also
observed a significant reduction in high glucose-induced caspase-3 activation in cells exposed to
metformin. A modest increase in caspase-3 activation was also seen in cells under normal culture
[basal] conditions. Pooled data from multiple experiments are provided in Figure 5-2 [Panel B].
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Figure 5-2: HG-mediated caspase-3 activation is reduced by metformin: Panel A: INS-1
832/13 cells were incubated with LG [2.5mM] and HG [20mM] in the absence and presence of
metformin [0-30 µM] for 24 h. Cell lysates were analyzed for caspase-3 using Western blotting.
Panel B: Densitometry was used to quantify the bands and the ratios were calculated over actin
in the presence of metformin. *p < 0.05 vs. 2.5mM glucose alone, **p < 0.05 vs. 20mM glucose
alone [n=3].
Metformin protects loss in cell viability induced by glucotoxic conditions in INS-1 832/13
cells
Compatible with above findings [Figure 5-2], we noticed significant protection by
metformin of HG-induced loss in metabolic cell viability in these cells [Figure 5-3]. Our findings
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demonstrated a significant reduction in metabolic cell viability in INS-1 832/13 cells incubated
under HG conditions. Co-provision of metformin significantly protected these cells from
metabolic alterations. Compatible with data described in the above sections, metformin treatment
alone markedly suppressed cell viability under basal glucose concentrations. These data clearly
imply dual regulatory roles of metformin.
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Figure 5-3: Cell viability assay: INS-1 832/13 cells were incubated with low [2.5 mM] or high
[20mM] glucose for 24 hrs in the absence or presence of metformin [30 µM]. After 24 hrs of
glucose treatment, the cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide [MTT] reagent for 4 hrs and absorbance was measured at 540 nm.
Data are represented as mean ± SEM from 8-10 determinations in each condition. *p=0.033, **
p=0.0001; and *** p=0.78 [not significant] vs. basal conditions.
Based on the findings described in these studies, we conclude that HG conditions
promote sustained activation and nuclear translocation of Rac1 and metabolic dysfunction
[CD36 expression, stress kinase activation, Bax activation, decreased Bcl2 activation, caspase-3
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activation and loss in metabolic cell viability] in pancreatic islet β-cells. We also provide
evidence in support of significant protection of these metabolic defects by metformin. Together,
these data provide evidence for novel targets for metformin, specifically at the level of pancreatic
β-cell.
Summary of findings:
 Metformin attenuated expression of one Bax isoform and showed no effect on Bcl2
expression
 Caspase-3 activation was inhibited by metformin in a dose dependent manner
 Cell viability loss due to glucotoxic conditions was also abrogated by metformin
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CHAPTER 6: DISCUSSION
It is well established that chronic exposure of pancreatic β-cells to HG conditions results
in significant metabolic alterations and dysfunction, including loss in cell proliferation and GSIS
leading to apoptotic demise of the β-cell [92]. More recent findings from our laboratory have
demonstrated novel regulatory roles for Rac1, a small G-protein, in the induction of islet β-cell
dysfunction under the duress of glucotoxicity [7, 34, 49, 93]. Specifically, we demonstrated that,
under glucotoxic conditions, sustained activation of Rac1 results in accelerated Nox2 signaling
leading to increased oxidative stress [ROS production], stress kinase [p38MAPK and p53]
activation, mitochondrial [caspase 3 activation] and nuclear [Lamin degradation] dysfunction
and cell death [7, 34, 49, 93, 94]. During these investigations, we also identified two guanine
nucleotide exchange factors [Tiam1 and Vav2] that mediate activation of Rac1 in eliciting
damaging effects on β-cells [33]. My studies described in this dissertation examined potential
alterations, if any, in the subcellular distribution [mislocalization] of Rac1 in pancreatic β-cells
exposed to glucotoxic conditions. Furthermore, I assessed the efficacy of metformin, an
antidiabetic drug, against HG-mediated effects on β-cell function. Salient findings from my
studies are exposure of INS-1 832/13 cells to HG-conditions result in nuclear association of
Rac1. I also demonstrated that clinically-relevant concentrations of metformin prevent HGinduced; [i] Rac1 activation and nuclear translocation; [ii] CD36 expression; [iii] stress kinase,
Bax and caspase-3 activation; and [iv] loss in cell viability. Implications of these findings in the
context of regulatory roles of constitutively-active Rac1 in the pathology of islet dysfunction,
and its prevention by metformin are discussed below.
Several recent studies from our laboratory have reported sustained activation of Rac1 in
clonal INS-1 832/13 β-cells, normal rodent islets, and human islets under the duress of metabolic
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stress, including glucotoxicity, lipotoxicity, exposure to proinflammatory cytokines, and
biologically-active sphingolipids, such as ceramide [7, 9, 33, 34, 49, 93, 95, 96]. These
observations were also confirmed in islets derived from type 2 DM animal models and human
donors with T2DM. Furthermore, pharmacological inhibition [NSC23766] of Tiam1, a GEF for
Rac1, attenuated Rac1 activation in all the above experimental conditions, thus suggesting that
Tiam1 represents one of the GEFs that mediate hyper-activation of Rac1. More importantly,
inhibition of Tiam1-Rac1 signaling axis also prevented HG-induced, Nox2 activation and
downstream stress kinase activation and mitochondrial dysfunction in pancreatic β-cells exposed
to HG conditions [33]. Together, these findings implicate Rac1 as a key mediator of islet β-cell
dysfunction in metabolic stress and diabetes.
Several recent studies have investigated beneficial effects of metformin against islet βcell function. It is noteworthy that these in vitro investigations utilized a wide range of
metformin concentrations [10 μM-1 mM]. For example, Simon-Szabo and associates [17] have
reported significant attenuation of palmitate-induced [lipoapoptosis] ER stress [elF2α
phosphorylation and CHOP expression] and stress kinase [JNK1/2] activation by metformin [10100 μM] in rat insulinoma cells. Using murine islets and human islets Lundquist et al. [97] have
demonstrated a marked reduction by metformin [20 μM] in nitric oxide synthase-derived nitric
oxide, insulin secretory dysfunction and loss in cell viability under conditions of long-term
exposure to glibenclamide and HG. Using rodent islets, Hashemitabar and associates have
demonstrated beneficial effects of metformin [15 μM] on insulin gene expression, insulin
secretion and islet cell viability [98]. Natalichhio and coworkers have shown significant
restoration of GLP-1 receptor impairment by metformin [0.5-1.0 mM] in murine islets following
exposure to palmitate [99]. Together, the above studies provide supporting evidence for
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beneficial/protective effects of metformin against gluco-, or lipotoxicity and ER stress. Our
current findings demonstrate marked protection of INS-1 832/13 cells, by metformin, against
HG-induced metabolic defects at concentrations as low as 30 µM.
A growing body of evidence implicates CD36, a fatty acid transport protein, in cell
apoptosis under glucolipotoxic conditions [26, 45]. Data from our current studies have provided
evidence to suggest that Rac1 activation is upstream to CD36 expression since EHT1864, a
known inhibitor of Rac1 [48, 100], attenuated HG-induced CD36 expression in INS-1 832/13
cells. Our findings are also compatible with recent observations of Elumalai and associates
demonstrating regulatory roles for Rac1-Nox2 signaling axis promotes CD36 expression in INS1 cells under the duress of glucotoxic conditions [45]. Using specific inhibitors of Tiam1-Rac1
[NSC23766] and Nox2 [VAS2870] these researchers were able to identify Tiam1-Rac1-Nox2
signaling steps as upstream modulators of CD36 expression under HG glucose exposure
conditions. It should be noted that the findings of Elumalai et al. [45] further validate our
original proposal that Tiam1-Rac1-Nox2 signaling pathway contributes to islet β-cell
dysfunction under metabolic stress conditions [33, 34, 93, 101]. Data from our current
investigations involving a structurally distinct inhibitor of Rac1 [EHT1864] further support this
working model. Our current observations also demonstrated a significant reduction in HGinduced CD36 expression by metformin at 30 μM concentration. Further, inhibition of Rac1CD36 pathway appears to regulate the downstream stress kinase [p38MAPK and p53] activation
and mitochondrial dysregulation [Bax and caspase-3 activation] in INS-1 832/13 cells. In further
support of our findings are the recent observations of Moon and associates demonstrating
significant protective effects of metformin [0.5 mM] against oxidative- and endoplasmic
reticulum stress-induced CD36 expression in clonal β-cells and rodent islets [26].
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It is noteworthy that metformin appears to exert dual regulatory roles in pancreatic βcells. For example, in the current studies, we consistently noted that under basal glucose
conditions, metformin increased Rac1-CD36-Stress kinase activation to a modest, but significant
degree while affording protection against HG-induced effects on these signaling steps. Along
these lines, using insulin-secreting MIN6 cells, Jiang and associates have provided evidence to
suggest dual regulatory roles for metformin in pancreatic β-cell function. First, under normal
growth conditions metformin significantly suppressed MIN6 cell proliferation and triggered
apoptosis via a mechanism involving AMPK-activation and autophagy-related signaling steps
[102]. Interestingly, however, metformin significantly protected MIN6 cells against palmitateinduced mitochondrial dysfunction [caspase activation] and cell death. While these data appear
to support our findings of significant protective effects of metformin on HG-induced effects in
INS-1 832/13 cells, it should be noted that studies of Jiang and associates [102] used relatively
high concentrations of metformin [2 mM] compared to much less concentration of metformin we
used in our current studies [15-30 μM].
Based on the available evidence, we propose a working model [Figure 6-1] that HGconditions stimulate Rac1 activation. It is also proposed that hyperactive Rac1 might regulate
other apoptotic function including CD36 expression, other stress kinase [p38MAPK and JNK1/2]
activation to initiate signaling events leading to mitochondrial dysregulation [Cleaved Caspase-3
and Bax activation] and nuclear collapse [Lamin-B degradation] terminating in loss in GSIS,
inhibition of proliferation and cellular apoptosis [7, 49, 94, 95]. We also propose that metformin
affords protection against above mentioned glucotoxic effects at clinically relevant
concentrations [15-30 μM]. Future studies will determine potential targets for metformin,
specifically regulatory factors for Rac1 activation including GEFs, GTPase-activating proteins
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and the Rho GDP dissociation inhibitor in the islet β-cell, the interplay of which is expected to
retain Rac1 in its active, GTP-bound conformation to promote downstream signaling events that
could contribute to metabolic dysregulation and onset of type 2DM [34, 103].

Glucotoxicity

EHT 1864 & Metformin

Vav2 activation

Rac1 activation

CD36expression

p38 &
JNK ½ activation

p53 activation

Mitochondrial
dysfunction

Caspase 3 activity

Bax

Bcl2

Cytochrome c
release

Apoptosis

Figure 6-1: A proposed model for metabolic stress induced dysfunction of pancreatic islet
β-cells: Reversal by metformin
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS
Based on the findings accrued in my studies, I conclude that hyperactive Rac1 might
regulate other apoptotic function including CD36 expression, other stress kinase [p38MAPK and
JNK1/2] activation to initiate signaling events leading to mitochondrial dysregulation and
nuclear collapse [Lamin-B degradation] terminating in loss in GSIS, inhibition of proliferation
and cellular apoptosis. My findings further support the existing evidence in the literature [7, 49,
94, 95]. My findings suggested that metformin affords protection against above mentioned
glucotoxic effects at clinically relevant concentrations [15-30 μM]. Future studies will determine
potential targets for metformin, specifically regulatory factors for Rac1 activation including
GEFs, GAPs and GDI in the islet β-cell, the interplay of which is expected to retain Rac1 in its
active, GTP-bound conformation to promote downstream signaling events that could contribute
to metabolic dysregulation and onset of type 2DM [34, 103].
Data from my studies are summarized below:
1. Metformin reduced the HG-induced Rac1 activation and nuclear translocation
2. HG-induced CD36 expression is downstream to Rac1 activation
3. EHT 1864 and metformin attenuated HG-induced CD36 expression
4. Metformin abrogated HG-induced p38MAPK and JNK 1 activation
5. HG-induced p53 activation was suppressed by metformin
6. Metformin inhibited one isoform of Bax and had no effect on Bcl2
7. Caspase-3 activation was reduced in a dose dependent manner by metformin
8. Metformin protected INS-1 832/13 cells against HG-induced loss in metabolic cell
viability.
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Future Directions:
The results from my studies have enriched our current understanding of how HGinduced small G-proteins (Rac1) activation and their mislocalization plays an important role
in activating fatty acid transporters, stress kinases, p53 and metabolic dysfunction, ultimately
leading to β-cell dysfunction and demise. My studies have also provided novel insights into
the mechanism of action of metformin in suppressing the sustained activation and
mistargetting [nuclear localization] of Rac1, thereby, eliciting protective effects on high
glucose-induced metabolic dysregulation of pancreatic β-cells. In my opinion, my work laid
foundation to future work in further validating my observations and hypothesis in in vivo
models of obesity , impaired insulin secretion and T2DM.
Following is the list of studies that need to be carried out to further assess the validity of my
model:
 Recent studies have reported that HG conditions promote the degradation of the
common α-subunit of FTase/GGTase, thereby causing Rac1 activation and
nuclear translocation, resulting in the activation of Rac1 mediated downstream
signaling mechanism contributing to β-cell death. It would we worthwhile to
assess protective effects of metformin against HG-induced defects in G-protein
prenylation in pancreatic β-cells.
 Furthermore, it is essential that we confirm our observations on potential
cytoprotective effects of metformin on HG-induced metabolic defects in primary
rodent and human islets.
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Glucotoxicity is the leading cause for β-cell dysfunction [e.g., defective glucosestimulated insulin secretion] in Type 2 Diabetes [T2DM]. Recent studies from our lab have
shown sustained Rac1 activation leading to the activation of downstream signaling steps
including stress kinase [p53, p38MAPK] activation and mitochondrial dysregulation [caspase-3
activation] in pancreatic islet beta-cells exposed to glucotoxic [HG] conditions [20 mM; 24 hrs].
Metformin [MF] is an oral anti-diabetic drug that is being widely prescribed to T2DM. MF
works by suppressing hepatic glucose production and increasing glucose uptake by the target
tissues. However, potential beneficial effects of MF on pancreatic beta-cell dysfunction under
HG conditions have not been studied to date. Therefore, in the current studies, we asked if MF
[0-30 μM; clinically relevant concentrations] affords protective effects against HG-induced
metabolic dysfunction of the pancreatic beta [INS-1 832/13] cells. Since recent studies from our
laboratory have demonstrated activation of Rac1, a small G-protein, as an upstream signaling
event to stress kinase activation, we asked if protective effects of MF may, in part, be due to
inhibition of HG-induced Rac1 activation in INS-1 832/13 cells. Data from these studies have
suggested nearly 40% inhibition in HG-induced Rac1 activation [3.43±0.57 fold over basal; n=4;
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p<0.05] by MF. Evidence is also presented to highlight novel roles for sustained activation of
Rac1 in HG-induced expression of Cluster of Differentiation 36 [CD36], a fatty acid transporter
protein, which is implicated in cell apoptosis. Western blot analysis indicated a significant
increase in the phosphorylation of p38MAPK [2.31±0.21 fold over basal; n=5; p<0.05], JNK1/2
and phosphorylation of p53 [4.42±1.20 fold over basal; n=3; p<0.05] in INS-1 832/13 cells. MF
[15µM] markedly attenuated HG-induced p38MAPK [74.8%], JNK 1 and p53 [55.7%]
activation under these experimental conditions. Our data from Bax phosphorylation [an indicator
of cell dysregulation] studies demonstrated an increase in the phosphorylation of two Bax
isoforms [Baxα by 1.63± 0.04 fold over basal; n=3; p<0.05; and Baxβ by 1.32±0.11 over basal;
n=3; p<0.05]. MF [30µM] attenuated the phosphorylation of only Baxα isoform [by 77.3%].
Lastly, our data also suggested that co-provision of MF significantly reduced [72.4%] HGinduced caspase-3 activation. Together, these findings suggest significant protection by MF
against HG-induced metabolic defects [activation of Rac1-stress kinase-caspase-3 signaling
module] in the islet beta-cell. Potential implications of these findings in the context of novel and
direct regulation of islet β-cell function by metformin are discussed.
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